Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00413270
First received: December 18, 2006
Last updated: July 12, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is no longer available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given